Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 22.5% in November
Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 22.5% in November
(Get Rating)Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 19,600 shares, an increase of 22.5% from the November 15th total of 16,000 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily volume of 16,900 shares, the short-interest ratio is presently 1.2 days.
Tempest Therapeutics, Inc.（納斯達克股票代碼：TPST —（獲取評級）是11月空頭利率大幅增加的受益者。截至11月30日，空頭利息總額爲19,600股，較11月15日的16,000股增加了22.5％。大約0.4％的股票被賣空。根據16,900股的平均每日交易量，空頭利率目前爲1.2天。
Analyst Ratings Changes
分析師評級變化
A number of research analysts have recently weighed in on TPST shares. William Blair restated an "outperform" rating on shares of Tempest Therapeutics in a research report on Tuesday, November 8th. LADENBURG THALM/SH SH started coverage on Tempest Therapeutics in a research report on Thursday, September 15th. They set a "buy" rating and a $8.00 price objective for the company.
許多研究分析師最近對TPST的股票進行了權衡。威廉·布萊爾在11月8日星期二的一份研究報告中重申了對Tempest Therapeutics股票的 “跑贏大盤” 的評級。LADENBURG THALM/SH SH在9月15日星期四的一份研究報告中開始報道Tempest Therapeutics。他們爲公司設定了 “買入” 評級和8.00美元的目標股價。
Institutional Inflows and Outflows
機構流入和流出
An institutional investor recently bought a new position in Tempest Therapeutics stock. Millennium Management LLC bought a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,675 shares of the company's stock, valued at approximately $29,000. Millennium Management LLC owned 0.13% of Tempest Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 50.26% of the company's stock.
一位機構投資者最近購買了Tempest Therapeutics股票的新頭寸。千禧管理有限責任公司在最近向美國證券交易委員會（SEC）提交的13F文件中顯示，該公司在第二季度購買了Tempest Therapeutics, Inc.（納斯達克股票代碼：TPST — 獲取評級）的新股份。該基金購買了該公司13,675股股票，價值約29,000美元。截至最近報告期末，千禧管理有限責任公司擁有Tempest Therapeutics0.13％的股份。對沖基金和其他機構投資者擁有該公司50.26％的股票。
Tempest Therapeutics Stock Up 2.7 %
暴風療法股票上漲2.7％
Tempest Therapeutics Company Profile
Tempest Therapeutics 公司
(Get Rating)
（獲取評級）
Tempest Therapeutics Inc, a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors.
Tempest Therapeutics Inc是一家處於臨床階段的腫瘤公司，致力於開發治療癌症的小分子療法。該公司的兩個臨床項目是 TPST-1495，前列腺素E2受體EP2和EP4的雙重拮抗劑，目前正在實體瘤中進行1期試驗；TPST-1120，一種過氧化物酶體增殖物激活受體α的選擇性拮抗劑，正在實體瘤中進行1期試驗。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Tempest Therapeutics (TPST)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 免費獲取 StockNews.com 關於 Tempest Therapeutics（TPST）的研究報告的副本
- 現在不是買入 Lennar 的時候但時機已到
- 馬倫汽車的改變遊戲規則的新聞
- 通貨膨脹和能源危機是兩列貨運列車相撞——以下是準備方法
- 企業產品合作伙伴的價值是否公平？
- WhatsApp 的合作伙伴關係會提升 MercadoLibre
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收Tempest Therapeutics日報的新聞和評級——在下方輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收Tempest Therapeutics及相關公司最新新聞的簡明每日摘要和分析師的評級。